Calypte Names President and Chief Operating Officer to Ensure a More Efficient Transition into Its Marketing and Sales Phase.

Business Editors/High-Tech Writers

ALAMEDA, Calif.--(BUSINESS WIRE)--June 3, 2003

Calypte Biomedical Corporation (OTCBB:CYPTV), the developer and marketer of the only two FDA-approved HIV-1 antibody tests that can be used on urine samples, as well as an FDA-approved serum HIV-1 antibody Western Blot supplemental test, today announced the appointment of Jay Oyakawa as president and chief operating officer.

"Jay has the necessary vision, background, energy and the demonstrated ability to deliver the results that this position requires," said Anthony Cataldo, Executive Chairman of Calypte Biomedical. "We were fortunate that we were able to find exactly who we needed to move this company forward as we complete our restructuring."

Commenting on his new appointment, Mr. Oyakawa stated, "My number one priority is to transition this company into a sales and marketing mode. We have an excellent product, leading-edge technology, and the potential to capture a significant share of the HIV testing market, particularly given that Calypte expects its urine-based rapid screening test to enter international markets within the next several months. Now that the federal government has given AIDS the priority it deserves, we fully intend to take advantage of our FDA-approved urine-based HIV-1 antibody test in order to become a significant player in the global marketplace."

Mr. Oyakawa has over 11 years of sales management experience, and previously held senior management positions in Los Angeles-based TechProdX, and NameSafe Inc., and a management position at Donaldson Lufkin & Jenrette Securities. Mr. Oyakawa earned his bachelor's degree in Economics at UCLA, and his MBA in Finance and Health Care at The Wharton School, University of Pennsylvania.

About Calypte Biomedical:

Calypte Biomedical Corporation headquartered in Alameda, California, is a public healthcare company dedicated to the development and commercialization of urine-based diagnostic products and services for Human Immunodeficiency Virus Type 1 (HIV-1), sexually transmitted diseases and other infectious diseases. Calypte's tests include the screening EIA and supplemental Western Blot tests, the only two FDA-approved HIV-1 antibody tests that can be used on urine samples. The company believes that accurate, non-invasive urine-based testing methods for HIV and other infectious diseases may make important contributions to public health by helping to foster an environment in which testing may be done safely, economically, and painlessly. Calypte markets its products in countries worldwide through international distributors and strategic partners. Current product labeling, including specific product performance claims, can be found at www.calypte.com.

Statements in this press release that are not historical facts are forward-looking statements, including statements regarding announcements of financial results and presentations by the Company. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, our ability to obtain additional financing that will allow us to continue our current and future operations and whether demand for our product and testing service in domestic and international markets will continue to expand. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company's success are more fully disclosed in the Company's most recent public filings with the U.S. Securities and Exchange Commission ("SEC"), including its annual report on Form 10-K for the year ended December 31, 2002, and its subsequent filings with the SEC.